Amedeo Smart

Free Medical Literature Service


 

Amedeo

Antiretroviral Therapy

  Free Subscription

Articles published in
JAMA
    March 2024
  1. SHETH AN, Momplaisir F, Dumond JB
    Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women.
    JAMA. 2024;331:912-914.
    >> Share

  2. MARRAZZO J, Tao L, Becker M, Leech AA, et al
    HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    JAMA. 2024 Mar 1. doi: 10.1001/jama.2024.0464.
    >> Share

    February 2024
  3. SARPATWARI A, Kohli S, Tu SS, Kesselheim AS, et al
    Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.
    JAMA. 2024 Feb 22:e240924. doi: 10.1001/jama.2024.0924.
    >> Share

  4. ALHIARY R, Gabriele S, Kesselheim AS, Tu SS, et al
    Delivery Device Patents on GLP-1 Receptor Agonists.
    JAMA. 2024 Feb 5:e240919. doi: 10.1001/jama.2024.0919.
    >> Share

    January 2024
  5. RUBIN R
    Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.
    JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28254.
    >> Share

    December 2023
  6. SURAN M
    Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID.
    JAMA. 2023 Dec 13. doi: 10.1001/jama.2023.24103.
    >> Share

    November 2023
  7. TU SS, Leadmon C, Daval CJR, Kesselheim AS, et al
    Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration-Regulated Products.
    JAMA. 2023 Nov 13:e2320196. doi: 10.1001/jama.2023.20196.
    >> Share

  8. NEGRO F, Lok AS
    Hepatitis D: A Review.
    JAMA. 2023 Nov 9. doi: 10.1001/jama.2023.23242.
    >> Share

    August 2023
  9. CHOU R, Spencer H, Bougatsos C, Blazina I, et al
    Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2023;330:746-763.
    >> Share

  10. RAGLOW Z, Malani PN, Petty LA
    Outpatient Treatment for COVID-19.
    JAMA. 2023 Aug 16. doi: 10.1001/jama.2023.16666.
    >> Share

  11. TU SS, Kesselheim AS, Wetherbee K, Feldman WB, et al
    Changes in the Number of Continuation Patents on Drugs Approved by the FDA.
    JAMA. 2023;330:469-470.
    >> Share

    June 2023
  12. HARRIS E
    FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9925.
    >> Share

    April 2023
  13. EGILMAN AC, Rome BN, Kesselheim AS
    Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
    JAMA. 2023;329:1283-1289.
    >> Share

    February 2023
  14. HARRIS E
    Paxlovid Alternative Is Similarly Effective.
    JAMA. 2023;329:622-623.
    >> Share

    December 2022
  15. SURAN M
    VA Finds Nirmatrelvir Associated With Lower Risk of Long COVID.
    JAMA. 2022;328:2386.
    >> Share

  16. HIGGINS AM, Berry LR, Lorenzi E, Murthy S, et al
    Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
    JAMA. 2022 Dec 16. doi: 10.1001/jama.2022.23257.
    >> Share

  17. KUEHN BM
    Inequity in Paxlovid Prescribing.
    JAMA. 2022;328:2203-2204.
    >> Share

  18. GANDHI RT, Bedimo R, Hoy JF, Landovitz RJ, et al
    Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.
    JAMA. 2022 Dec 1. doi: 10.1001/jama.2022.22246.
    >> Share

    October 2022
  19. LARKIN HD
    Paxlovid Drug Interaction Screening Checklist Updated.
    JAMA. 2022;328:1290.
    >> Share

    September 2022
  20. LARKIN HD
    Paxlovid Expiration Dates Extended.
    JAMA. 2022;328:819.
    >> Share

    July 2022
  21. KUEHN BM
    Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.
    JAMA. 2022;328:323.
    >> Share

    June 2022
  22. RUBIN R
    From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
    JAMA. 2022 Jun 8. pii: 2793357. doi: 10.1001/jama.2022.9925.
    >> Share

    January 2022
  23. GANDHI RT, Malani PN, Del Rio C
    COVID-19 Therapeutics for Nonhospitalized Patients.
    JAMA. 2022 Jan 14. pii: 2788254. doi: 10.1001/jama.2022.0335.
    >> Share

  24. BORIO LL, Bright RA, Emanuel EJ
    A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
    JAMA. 2022 Jan 6. pii: 2787946. doi: 10.1001/jama.2021.24165.
    >> Share

    May 2020
  25. SLOMSKI A
    No Benefit for Lopinavir-Ritonavir in Severe COVID-19.
    JAMA. 2020;323:1999.
    >> Share

  26. SANDERS JM, Monogue ML, Jodlowski TZ, Cutrell JB, et al
    Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    JAMA. 2020;323:1824-1836.
    >> Share

    March 2020
  27. YOUNG BE, Ong SWX, Kalimuddin S, Low JG, et al
    Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
    JAMA. 2020 Mar 3. pii: 2762688. doi: 10.1001/jama.2020.3204.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016